Atrial fibrillation: is pulsed technology the new frontier?
It is one of the most effective strategies, particularly when carried out in the early stages of the disease, when the patient’s heart is still structurally healthy
Key points
Atrial fibrillation is the most common cardiac arrhythmia in Italia, with around 1.1 million diagnosed patients. It affects 1–2 per cent of the general population and over 8 per cent of those aged over 65, representing one of the main causes of ischaemic stroke and A&E visits. Due to the progressive ageing of the population, it is estimated that the number of cases will almost double, reaching around 2 million by 2060.
This is a phenomenon which, on the one hand, reflects advances in medicine and improvements in quality of life, enabling people to live longer; on the other hand, it poses significant challenges in terms of care and organisation, as these patients require a continuous course of treatment and monitoring.
Increasingly effective treatments
“Today we have increasingly effective therapeutic tools for the management of atrial fibrillation,” emphasises Patrizio Mazzone, Head of Cardiology 3 – Electrophysiology, Niguarda Hospital in Milan. “On the one hand, we have new medicines, particularly for the prevention and treatment of heart failure; on the other, we can rely on anticoagulants that we have been using for some time and which have proven highly effective in reducing the risk of thromboembolic events.” The most significant development, however, concerns technology. “In recent years,” he continues, “we have seen significant advances in the devices and materials used for transcatheter ablation, a procedure that is now one of the most effective strategies for treating atrial fibrillation, particularly when performed in the early stages of the disease, whilst the patient’s heart is still structurally healthy.”
What is Pulsed Field Ablation
Ablation has now been in use for some thirty years, “but a new form of energy, known as Pulsed Field Ablation (PFA) and based on the principle of electroporation, has recently become established. This technology is significantly changing our approach to the procedure”.
PFA uses ultra-rapid electrical pulses to selectively target and neutralise only the diseased heart cells, whilst sparing surrounding tissues such as nerves and the oesophagus. However, given the steadily rising prevalence of atrial fibrillation, access to ablation therapy is still not commensurate with the number of patients who could potentially benefit from it. This situation is due to a number of factors.
